UBS Group
RDHL

UBS Group’s Redhill Biopharma RDHL Stock Holding History

UBS Group’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85 Sell
100
-726
-88% -$670 ﹤0.01% 10128
2026
Q1 		$615 Buy
826
+808
+4,489% +$851 ﹤0.01% 9807
2025
Q4 		$18 Sell
18
-5
-22% -$7 ﹤0.01% 10361
2025
Q3 		$50 Sell
23
-7,965
-100% -$13K ﹤0.01% 10024
2025
Q2 		$15.5K Buy
7,988
+7,985
+266,167% +$16.3K ﹤0.01% 8607
2025
Q1 		$8 Sell
3
-4,364
-100% -$20.3K ﹤0.01% 10128
2024
Q4 		$27.1K Buy
4,367
+4,364
+145,467% +$33.4K ﹤0.01% 7680
2024
Q3 		$26 Sell
3
-5,692
-100% -$56K ﹤0.01% 9290
2024
Q2 		$52.8K Buy
5,695
+3,671
+181% +$40.7K ﹤0.01% 6649
2024
Q1 		$26.8K Buy
2,024
+2,020
+50,500% +$36K ﹤0.01% 6784
2023
Q4 		$152 Buy
4
+1
+33% +$20 ﹤0.01% 8863
2023
Q3 		$36 Sell
3
-20
-87% -$523 ﹤0.01% 9054
2023
Q2 		$689 Sell
23
-46
-67% -$2.65K ﹤0.01% 8131
2023
Q1 		$7.08K Buy
69
+66
+2,200% +$12.5K ﹤0.01% 7850
2022
Q4 		$405 Sell
3
-4
-57% -$1.73K ﹤0.01% 10202
2022
Q3 		$3K Sell
7
-12
-63% -$10.5K ﹤0.01% 9570
2022
Q2 		$17K Buy
19
+2
+12% +$2.74K ﹤0.01% 7109
2022
Q1 		$44K Sell
17
-224
-93% -$531K ﹤0.01% 6627
2021
Q4 		$622K Buy
241
+140
+139% +$560K ﹤0.01% 4805
2021
Q3 		$462K Buy
101
+7
+7% +$47.5K ﹤0.01% 4791
2021
Q2 		$645K Buy
94
+55
+141% +$380K ﹤0.01% 4536
2021
Q1 		$286K Sell
39
-11
-22% -$92.3K ﹤0.01% 5237
2020
Q4 		$401K Buy
50
+45
+900% +$404K ﹤0.01% 4780
2020
Q3 		$55K Buy
5
+3
+150% +$24.6K ﹤0.01% 5583
2020
Q2 		$16K Hold
2
– – ﹤0.01% 6700
2020
Q1 		$11K Hold
2
– – ﹤0.01% 6877
2019
Q4 		$15K Hold
2
– – ﹤0.01% 7063
2019
Q3 		$17K Sell
2
-1
-33% -$7.28K ﹤0.01% 6832
2019
Q2 		$23K Sell
3
-2
-40% -$15.4K ﹤0.01% 6519
2019
Q1 		$41K Buy
5
+3
+150% +$23.7K ﹤0.01% 5706
2018
Q4 		$13K Sell
2
-5
-71% -$38.3K ﹤0.01% 7100
2018
Q3 		$62K Buy
7
+4
+133% +$32.6K ﹤0.01% 5993
2018
Q2 		$26K Hold
3
– – ﹤0.01% 6511
2018
Q1 		$14K Buy
3
+1
+50% +$5.76K ﹤0.01% 6662
2017
Q4 		$10K Hold
2
– – ﹤0.01% 7032
2017
Q3 		$22K Hold
2
– – ﹤0.01% 6378
2017
Q2 		$19K Sell
2
-2
-50% -$19.2K ﹤0.01% 6343
2017
Q1 		$40K Buy
4
+2
+100% +$20K ﹤0.01% 5684
2016
Q4 		$21K Hold
2
– – ﹤0.01% 6485
2016
Q3 		$28K Hold
2
– – ﹤0.01% 6005
2016
Q2 		$22K Hold
2
– – ﹤0.01% 6223
2016
Q1 		$25K Hold
2
– – ﹤0.01% 6039
2015
Q4 		$26K Hold
2
– – ﹤0.01% 6471
2015
Q3 		$19K Hold
2
– – ﹤0.01% 6749
2015
Q2 		$40K Buy
2
+1
+100% +$15.9K ﹤0.01% 6199
2015
Q1 		$11K Buy
+1
New +$14.2K ﹤0.01% 7567
2014
Q4 		– Hold
0
– – – 8987

Other funds holding RDHL

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SAM
Smartleaf Asset Management Boston, Massachusetts $3.08B AUM 27.39% 1-Year Est. Return

UBS Group's RDHL Position: Q2 2026 in Review

UBS Group reduced its Redhill Biopharma (RDHL) stake by 88% in Q2 2026, selling an estimated $670 and leaving 100 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #10128.

UBS Group first reported a position in RDHL in Q1 2015 and has held it in 46 quarters since. The position peaked at $645K in Q2 2021. 14 funds tracked by Wall St. Rank hold RDHL as of Q2 2026.

  • UBS Group held 100 shares of Redhill Biopharma worth $85 as of Q2 2026.
  • UBS Group sold 726 Redhill Biopharma shares in Q2 2026, an estimated $670.
  • Redhill Biopharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10128 holding.
  • UBS Group first reported a position in Redhill Biopharma in Q1 2015 and has held it in 46 quarters since.
  • UBS Group's Redhill Biopharma position peaked at $645K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.